Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patients

Table 4 Comparison of CR rate among genotypes after two courses of Ara-C based chemotherapy

Genotype	Total (n)	CR (n, %)	Non-CR (n, %)	OR (95% CI)	p	OR (95% CI)^a	p^a
rs4082155
AA	157	96 (61.1%)	61 (38.9%)	1.00 (reference)		1.00 (reference)
AG	266	184 (69.2%)	82 (30.8%)	0.701 (0.464–1.060)	0.092	0.562 (0.340–0.931)	0.025*
GG	123	88 (71.5%)	35 (28.5%)	0.626 (0.377–1.039)	0.07	0.501 (0.265–0.946)	0.033*
AA	157	96 (61.1%)	61 (38.9%)	1.00 (reference)		1.00 (reference)
AG + GG	389	272 (69.9%)	117 (30.1%)	0.677 (0.460–0.997)	0.048*	0.544 (0.338–0.876)	0.012*
rs6767907
GG	237	155 (65.4%)	82 (34.6%)	1.00 (reference)		1.00 (reference)
GA	242	171 (70.7%)	71 (29.3%)	0.698 (0.396–1.230)	0.213	0.668 (0.323–1.379)	0.275
AA	67	42 (62.7%)	25 (37.3%)	0.889 (0.506–1.560)	0.681	1.126 (0.548–2.317)	0.746
rs76208147
CC	422	273 (64.7%)	149 (35.3%)	1.00 (reference)		1.00 (reference)
CT	110	84 (76.4%)	26 (23.6%)	0.567 (0.350–0.919)	0.021*	0.600 (0.342–1.053)	0.075
TT	14	11 (78.6%)	3 (21.2%)	0.500 (0.137–1.819)	0.293	0.545 (0.114–2.604)	0.447